- £349.64m
- £236.66m
- £167.72m
- 82
- 78
- 77
- 94
2019 March 31st | R2020 March 31st | R2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 212 | 144 | 128 | 145 | 168 |
Cost of Revenue | |||||
Gross Profit | 98.3 | 91.1 | 82.3 | 96.4 | 103 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 157 | 93.8 | 106 | 94.6 | 123 |
Operating Profit | 54.9 | 50.5 | 21.8 | 50.5 | 45.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 54.7 | 50 | 20.4 | 48.5 | 42.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | 44.4 | 40 | 15.9 | 39.5 | 34.7 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 44.4 | 45.7 | 22.3 | 69.5 | 34.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 44.4 | 45.7 | 22.3 | 69.5 | 34.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.639 | 0.586 | 0.272 | 0.537 | 0.574 |
Dividends per Share |